Literature DB >> 7936284

Do parkinsonian symptoms and levodopa-induced dyskinesias start in the foot?

M Vidailhet1, A M Bonnet, R Marconi, N Gouider-Khouja, Y Agid.   

Abstract

Parkinsonian symptoms and levodopa-induced dyskinesias (LIDs) are often considered to occur first, and to predominate, in the upper limbs. We studied the topography, type, sequence, and severity of LIDs in 20 consecutive patients with Parkinson's disease (PD) experiencing LIDs for less than 6 months (Hoehn and Yahr stage II-III; average age at onset of PD, 57 years; average duration of PD, 7.2 years; percent of improvement with levodopa > 50) and compared them with the initial site, form, and evolution of the patient's motor disability. Parkinsonism started in the foot in six of 20 patients. Motor disability in the "off" state was similar in upper and lower extremities, except for akinesia, which was worse in the lower limbs. A careful interview indicated that LIDs had started in the foot in all patients. After administration of a single dose of levodopa ("levodopa test"), LIDs appeared in all patients as dystonia of the foot homolateral to the side most affected by PD (onset-of-dose dyskinesia). LIDs were preceded by "off" dystonia (dystonic foot) in six patients and were followed by mid-dose dyskinesia in eight. This is consistent with an early loss of dopaminergic innervation corresponding somatotopically to the foot area. The similarities among initial LIDs, early morning dystonia, and onset-of-dose dyskinesia suggest a similar pathophysiology.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7936284     DOI: 10.1212/wnl.44.9.1613

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

1.  "Silly walks" in Parkinson's disease: unusual presentation of dopaminergic-induced dyskinesias.

Authors:  Evžen Růžička; Kateřina Zárubová; John G Nutt; Bastiaan R Bloem
Journal:  Mov Disord       Date:  2011-04-14       Impact factor: 10.338

Review 2.  Psychomotor retardation in depression: biological underpinnings, measurement, and treatment.

Authors:  Jeylan S Buyukdura; Shawn M McClintock; Paul E Croarkin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-10-31       Impact factor: 5.067

Review 3.  Treating and preventing levodopa-induced dyskinesias: current and future strategies.

Authors:  F Durif
Journal:  Drugs Aging       Date:  1999-05       Impact factor: 3.923

4.  Onset pattern of nigrostriatal denervation in early Parkinson's disease.

Authors:  José A Pineda-Pardo; Álvaro Sánchez-Ferro; Mariana H G Monje; Nicola Pavese; José A Obeso
Journal:  Brain       Date:  2022-04-29       Impact factor: 15.255

Review 5.  Levodopa-induced dyskinesias and their management.

Authors:  Francesca Del Sorbo; Alberto Albanese
Journal:  J Neurol       Date:  2008-08       Impact factor: 4.849

6.  Age at onset and Parkinson disease phenotype.

Authors:  Gennaro Pagano; Nicola Ferrara; David J Brooks; Nicola Pavese
Journal:  Neurology       Date:  2016-02-10       Impact factor: 9.910

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.